Impressive Results of SYFOVRE in GALE Extension Study for Geographic Atrophy
Monday, 10 June 2024, 08:24
Sustained Visual Function in Atrophic Patients
SYFOVRE (pegcetacoplan injection) has shown remarkable efficacy in maintaining visual function over a 36-month period in the GALE Extension Study focused on Geographic Atrophy (GA).
Promising Long-term Effects
- GALE Extension Study: Demonstrates sustained benefits of SYFOVRE
- Key Insight: SYFOVRE's potential in addressing visual impairments
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.